GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alpine Immune Sciences Inc (FRA:34LA) » Definitions » 3-Year EPS without NRI Growth Rate

Alpine Immune Sciences (FRA:34LA) 3-Year EPS without NRI Growth Rate : 21.80% (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Alpine Immune Sciences 3-Year EPS without NRI Growth Rate?

Alpine Immune Sciences's EPS without NRI for the three months ended in Mar. 2024 was €-0.26.

During the past 3 years, the average EPS without NRI Growth Rate was 21.80% per year. During the past 5 years, the average EPS without NRI Growth Rate was 18.90% per year. During the past 10 years, the average EPS without NRI Growth Rate was 20.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 12 years, the highest 3-Year average EPS without NRI Growth Rate of Alpine Immune Sciences was 36.00% per year. The lowest was -24.70% per year. And the median was 15.10% per year.


Competitive Comparison of Alpine Immune Sciences's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, Alpine Immune Sciences's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alpine Immune Sciences's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alpine Immune Sciences's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Alpine Immune Sciences's 3-Year EPS without NRI Growth Rate falls into.



Alpine Immune Sciences 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Alpine Immune Sciences  (FRA:34LA) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Alpine Immune Sciences 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Alpine Immune Sciences's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Alpine Immune Sciences (FRA:34LA) Business Description

Traded in Other Exchanges
Address
188 East Blaine Street, Suite 200, Seattle, WA, USA, 98102
Alpine Immune Sciences Inc is a clinical-stage biopharmaceutical company dedicated to discovering and developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. Its approach includes a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics. Its pipeline candidates are; ALPN-303, or povetacicept, is a dual antagonist of the B cell activating factor, or BAFF, and a proliferation-inducing ligand, or APRIL, cytokines, which play key roles in the activation, development, and survival of B cells, and ALPN-101, or acazicolcept, is a dual Inducible T cell Costimulator, or ICOS, and CD28 antagonist intended for the treatment of autoimmune and inflammatory diseases.

Alpine Immune Sciences (FRA:34LA) Headlines

No Headlines